A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2017
At a glance
- Drugs Lanabecestat (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms DAYBREAK; DAYBREAK-ALZ
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 28 Jun 2016 Status changed from not yet recruiting to recruiting.
- 24 May 2016 Status changed from planning to not yet recruiting.